All Updates

All Updates

icon
Filter
Earnings/results
Elevation Oncology misses analyst consensus; reports wider net losses for Q4 2022 and full-year
Precision Medicine
Mar 9, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

Mar 9, 2023

Elevation Oncology misses analyst consensus; reports wider net losses for Q4 2022 and full-year

Earnings/results

  • Elevation Oncology reported a net loss per share of USD 0.82 in Q4 2022, missing analyst expectations by 5.1%. Net loss for the quarter increased significantly by 97.9% YoY to USD 19 million. Net losses for the full financial year 2022 also worsened by almost 2x YoY to USD 95.1 million. Elevation Oncology is a clinical-stage company that does not generate any drug sales.  

  • The significant increase in net losses for Q4 2022 was mainly attributable to the increase in R&D expenses which rose by more than 2x YoY, primarily due to seribantumab manufacturing and clinical trial expenses. Further, administration costs increased by 17.6% to USD 4 million due to an increase in personnel costs. 

  • The company expects to achieve a few milestones for 2023 which include: 1) plans to present preclinical proof-of-concept data of EO-3021 at a medical conference in 1H 2023 and 2) expects to initiate Phase I clinical trial of EO-3021 in the US in 2H 2023. 

  • Cash and cash equivalents stood at USD 90.3 million at the end of December 2022, decreasing from USD 107.9 million in September 2022. It expects to extend its cash runway till 2024.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.